Short interest for DexCom gives investors a sense of the degree to which investors are betting on the decline of DexCom's stock. Short interest data is updated every two weeks.

DexCom Stock (NASDAQ:DXCM), Short Interest Report

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Aon - logo

News

Intraday Update

Markets

Movers

ACCD

ACMR

ACON

AILE

AIRE

ALSN

APPF

ARCB

ATXI

BACK

BDRX

CGEM

CSSE

DXCM

ELWS

EXPO

FCUV

FRGT

GOOG

GOOGL

ICLK

INTC

KNSL

KTOS

Kintara Therapeutics, Inc. - Common Stock

KTRA

Eaton Vance Massachusetts Municipal Income Trust

NIVF

NUWE

NWGL

ODFL

PCSA

PEGY

RERE

ROKU

SAIA

SBFM

SGBX

SKIL

SLCA

SNAP

TEAM

TNET

TVGN

VINC

WORX

ZVSA

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Google Parent Alphabet

Pre-Market Outlook

Nuveen Insured California Premium Fund Ii

Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

intel laptop manufacturing

TDOC

Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

DexCom Inc

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 25.99% on an annualized basis producing an average annual return of 38.03%. Currently, DexCom has a market capitalization of $50.89 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 15 years ago, it would be worth $127,970.00 today based on a price of $127.97 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714494626_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today

Shares of Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/AON/earnings">quarterly financial results</a>.
Aon posted adjusted earnings of $5.66 per share, missing market estimates of $5.91 per share. The company's sales came in at $4.070 billion versus expectations of $4.126 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Aon shares dipped 7.4% to $283.19 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares jumped 73.3% to $1.2475 after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 63% to $0.0845.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares gained 55% to $2.01 after dipping 16% on Thursday.</li>
<li>Universal Logistics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) surged 45.2% to $47.76 after the company reported better-than-expected first-quarter financial results.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) jumped 40% to $0.3967 after the company announced board approval for the spin-off of Lusher.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 37% to $2.68.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) gained 29% to $0.6502. Concord Medical filed 2023 annual report on Form 20-F.</li>
<li>Exponent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPO#NASDAQ">EXPO</a>) shares climbed 28.5% to $102.41 after the company reported better-than-expected first-quarter financial results.</li>
<li>Skillsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKIL#NYSE">SKIL</a>) climbed 26.4% to $8.60.</li>
<li>MultiMetaVerse Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMV#NASDAQ">MMV</a>) gained 24.2% to $0.61.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) gained 23% to $14.02 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates. Also, the company reported a year-over-year increase in quarterly daily active users.</li>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) surged 22.2% to $16.98 after the company reported better-than-expected first-quarter financial results and issued FY24 EPS guidance.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) surged 22.2% to $0.9888.</li>
<li>U.S. Silica Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLCA#NYSE">SLCA</a>) gained 20% to $15.67 after the company reported first-quarter financial results and entered into a definitive agreement to be acquired by funds managed by affiliates of Apollo.</li>
<li>Earlyworks Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) rose 19.7% to $0.8725 after gaining 19% on Thursday.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) surged 19.5% to $23.03.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares gained 19.3% to $1.0150 after falling over 43% on Thursday.</li>
<li>ATRenew Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NASDAQ">RERE</a>) surged 18.9% to $1.9150. ATRenew announced appointment of new director.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) gained 17.5% to $13.39.</li>
<li>Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) climbed 17% to $1.0702 after gaining 5% on Thursday.</li>
<li>Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) shares gained 16% to $68.20 after the company reported better-than-expected first-quarter FY24 earnings.</li>
<li>AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) surged 16% to $251.22 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) gained 15% to $7.97 after the company reported better than expected first-quarter earnings and issued guidance.</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) shares rose 13.7% to $208.63 after the company reported better-than-expected third-quarter financial results.</li>
<li>Rogers Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) surged 12.7% to $123.46 after the company beat first-quarter EPS and sales estimates.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) gained 11.3% to $7.92</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) rose 10.6% to $172.52 the company posted upbeat results for its first quarter. Alphabet's board authorized an additional share repurchase program of up to $70 billion and also announced its first-ever quarterly dividend.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) gained 8.8% to $18.80 after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $20 to $27.</li>
<li>AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) climbed 8.6% to $174.20 following second-quarter results.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares gained 8.4% to $0.8725 after gaining 15% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) shares fell 48.8% to $1.31 after the company announced the termination of its merger agreement.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) fell 46.7% to $0.1540 after the company reported pricing of $2.7 million public offering.</li>
<li>Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) fell 27.7% to $0.1584.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) dipped 25.3% to $0.5752.</li>
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) fell 24.5% to $12.71.</li>
<li>IMAC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) dipped 22.9% to $3.93.</li>
<li>reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) fell 20.8% to $1.10.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) fell 19.3% to $4.84.</li>
<li>Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) dipped 19.1% to $439.40 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Kinsale Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) fell 17.3% to $374.29 following first-quarter results.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) fell 15.5% to $0.3319. Aclarion shares jumped 36% on Thursday after the company announced that its Nociscan solution will be used in the upcoming LIFEHAB trial evaluating the diagnosis and treatment of chronic low back pain.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) fell 15% to $4.5250 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) shares declined 14.8% to $53.55 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) fell 13.5% to $7.59.</li>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) fell 12.7% to $0.2260 after dipping 39% on Thursday. Chicken Soup For The Soul Entertainment received delinquency letter from the Nasdaq.</li>
<li>TriNet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) fell 11.5% to $112.11 after the company reported worse-than-expected first-quarter results and issued weak guidance.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares fell 11.1% to $31.23 after the company reported worse-than-expected first-quarter sales results and issued EPS guidance below estimates.</li>
<li>Accolade, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) dipped 10.6% to $8.22 following quarterly results.</li>
<li>XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) fell 10.2% to $106.14.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) shares fell 9.4% to $179.76 after the company reported third-quarter financial results. Atlassian said Scott Farquhar has decided to step down from his role as co-CEO, effective Aug. 31. Cannon-Brookes will continue to lead Atlassian as CEO.</li>
<li>Vincerx Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares fell 8.8% to $0.8180 after the company announced pricing of underwritten public offering of common stock and warrants.</li>
<li>SCWorx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) fell 8.7% to $2.52 after surging 36% on Thursday.   </li>
<li>ACM Research, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) fell 8.3% to $25.94 after announcing preliminary unaudited revenue and shipments for the first quarter.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares fell 8.2% to $57.63 after the company reported first-quarter financial results.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) fell 7.8% to $2.52. Processa Pharmaceuticals shares jumped 50% on Thursday after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and announced an $8 price target.</li>
<li>Red Rock Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) dipped 7.4% to $54.83.</li>
<li>ArcBest Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) declined 7.3% to $128.07.</li>
<li>Allison Transmission Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) fell 6.6% to $74.97 following first-quarter results.</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) fell 6.2% to $184.41.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 6.3% to $129.17 after the company reported first-quarter financial results.</li>
<li>Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) fell 4% to $116.44 following weak earnings.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38459594/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q1 Earnings</a>

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Raymond James analyst Jayson Bedford maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Strong Buy and raises the price target from $151 to $160.

Price Target

Analyst Ratings

Raymond James Maintains Strong Buy on DexCom, Raises Price Target to $160

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $144 to $145.

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $145

Shares of Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) rose sharply in today's pre-market trading the company posted upbeat <a href="https://www.benzinga.com/news/earnings/24/04/38445001/alphabet-q1-earnings-revenue-beat-eps-beat-70b-buyback-first-ever-dividend-ai-leadership-and-more">results for its first quarter</a>.
Google parent Alphabet said its first-quarter revenue increased 15% year-over-year to $80.539 billion, beating the consensus estimate of $78.594 billion. The company reported quarterly earnings of $1.89 per share, beating analyst estimates of $1.51 per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Alphabet's board authorized an additional share repurchase program of up to $70 billion and also announced its first-ever quarterly dividend.
Alphabet shares jumped 11.9% to $174.58 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
<ul>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares gained 64.7% to $1.40 in pre-market trading after falling over 43% on Thursday.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 40.5% to $0.0729 in pre-market trading.</li>
<li>Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) climbed 32.4% to $1.21 in pre-market trading after gaining 5% on Thursday.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) gained 24.2% to $14.16 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates. Also, the company reported a year-over-year increase in quarterly daily active users.</li>
<li>Earlyworks Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) rose 20.7% to $0.88 in today's pre-market trading after gaining 19% on Thursday.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares gained 20.1% to $0.1898 in pre-market trading after gaining 15% on Thursday.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares gained 14.6% to $1.49 in pre-market trading after dipping 16% on Thursday.</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) shares rose 11.5% to $204.50 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) shares gained 11% to $65.30 in pre-market trading after the company reported better-than-expected first-quarter financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) fell 19.5% to $0.3161 in pre-market trading. Aclarion shares jumped 36% on Thursday after the company announced that its Nociscan solution will be used in the upcoming LIFEHAB trial evaluating the diagnosis and treatment of chronic low back pain.</li>
<li>Vincerx Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares declined 16.4% to $0.75 in pre-market trading after the company announced pricing of underwritten public offering of common stock and warrants.</li>
<li>SCWorx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) fell 16.3% to $2.31 pre-market trading after surging 36% on Thursday.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) fell 15.4% to $2.05 in pre-market trading. Processa Pharmaceuticals shares jumped 50% on Thursday after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and announced an $8 price target.</li>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) fell 13.9% to $0.2238 pre-market trading after dipping 39% on Thursday. Chicken Soup For The Soul Entertainment received delinquency letter from the Nasdaq.</li>
<li>Northann Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCL#NYSE">NCL</a>) shares fell 13.6% to $0.4015 in pre-market trading after dipping 12% on Thursday.</li>
<li>Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) shares declined 12.6% to $55.00 in pre-market trading after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares fell 7.2% to $32.57 in pre-market trading after the company reported worse-than-expected first-quarter sales results and issued EPS guidance below estimates.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares fell 5.8% to $4.41 in pre-market trading after dipping 19% on Thursday.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 5.3% to $130.70 in pre-market trading after the company reported first-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38452338/microsoft-alphabet-and-3-stocks-to-watch-heading-into-friday">Microsoft, Alphabet And 3 Stocks To Watch Heading Into Friday</a>

WIIM

DexCom shares are trading lower. The company reported Q1 financial results.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Friday.
Shares of Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares fell sharply in today&#8217;s pre-market trading after the company reported worse-than-expected first-quarter sales results and issued EPS <a href="https://www.benzinga.com/news/earnings/24/04/38444720/intel-shares-fall-on-q1-revenue-miss-weak-q2-eps-guidance">guidance below estimates.</a>
Quarterly sales came in at $12.72 billion, which missed the analyst consensus estimate of $12.78 billion. Intel said it sees second-quarter earnings of 10 cents per share, versus the 10 cent estimate, and revenue in a range of $12.5 billion to $13.5 billion, versus the $12.68 billion estimate, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Intel shares tumbled 7.2% to $32.57 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) shares declined 12.6% to $55.00 in pre-market trading after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares fell 5.8% to $4.41 in pre-market trading after dipping 19% on Thursday.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 5.3% to $130.70 in pre-market trading after the company reported first-quarter financial results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) shares fell 5.3% to $188.00 in pre-market trading after the company reported third-quarter financial results. Atlassian said Scott Farquhar has decided to step down from his role as co-CEO, effective Aug. 31. Cannon-Brookes will continue to lead Atlassian as CEO.</li>
<li>ACM Research, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) fell 4.6% to $27.00 pre-market trading after announcing preliminary unaudited revenue and shipments for the first quarter.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares slipped 4.3% to $12.76 in pre-market trading following a wider-than-expected quarterly loss.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares fell 4.2% to $60.17 in pre-market trading after the company reported first-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38452336/investor-sentiment-improves-slightly-but-dow-tumbles-over-350-points">Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 51.8% to $1.29 during Thursday's after-market session. The company's market cap stands at $212.3 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock rose 10.61% to $0.64. The company's market cap stands at $15.6 million. </li>
<li>ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) stock rose 6.85% to $196.0. The market value of their outstanding shares is at $28.8 billion. The company's, Q3 earnings came out today. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares increased by 5.51% to $0.99. The market value of their outstanding shares is at $15.6 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock increased by 4.99% to $0.7. The market value of their outstanding shares is at $158.6 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares increased by 4.98% to $0.35. The market value of their outstanding shares is at $10.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares declined by 17.5% to $0.74 during Thursday's after-market session. The company's market cap stands at $15.8 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock declined by 16.56% to $0.33. The market value of their outstanding shares is at $2.3 million. </li>
<li>DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) stock decreased by 8.7% to $126.01. The company's market cap stands at $49.9 billion. As per the press release, Q1 earnings came out today. </li>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) shares fell 7.99% to $0.27. The market value of their outstanding shares is at $26.7 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 7.41% to $1.0. The market value of their outstanding shares is at $1.4 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock decreased by 6.3% to $2.68. The company's market cap stands at $21.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFRG

DARE

FRES

GOSS

LIFW

TBIO

TIVC

12 Health Care Stocks Moving In Thursday's After-Market Session

DexCom's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) short percent of float has fallen 8.15% since its last report. The company recently reported that it has 14.57 million shares sold short, which is 4.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>DexCom Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714076112_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for DexCom has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing DexCom's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DexCom's peer group average for short interest as a percentage of float is 4.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into DexCom's Recent Short Interest

Guidance

DexCom Sees FY24 Revenue $4.20B-$4.35B Vs $4.326B Est.

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.27 by 18.52 percent. The company reported quarterly sales of $921.000 million which beat the analyst consensus estimate of $909.238 million by 1.29 percent. This is a 24.21 percent increase over sales of $741.500 million the same period last year.

Earnings

Earnings Beats

DexCom Q1 2024 Adj EPS $0.32 Beats $0.27 Estimate, Sales $921.000M Beat $909.238M Estimate

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 5 years by 23.93% on an annualized basis producing an average annual return of 35.38%. Currently, DexCom has a market capitalization of $51.74 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 5 years ago, it would be worth $4,603.38 today based on a price of $134.20 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713380445_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today

Deep-pocketed investors have adopted a bullish approach towards DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DXCM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for DexCom. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 5 are puts, totaling $243,316, and 5 are calls, amounting to $151,590.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $175.0 for DexCom over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for DexCom's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DexCom's whale trades within a strike price range from $120.0 to $175.0 in the last 30 days. 
<h3>DexCom 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712867556_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$7.4</td>
<td>$7.2</td>
<td>$7.4</td>
<td>$125.00</td>
<td>$63.6K</td>
<td style="text-align: right;">23</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.3</td>
<td>$7.1</td>
<td>$7.3</td>
<td>$120.00</td>
<td>$58.4K</td>
<td style="text-align: right;">56</td>
<td style="text-align: right;">235</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.5</td>
<td>$17.2</td>
<td>$17.5</td>
<td>$140.00</td>
<td>$52.5K</td>
<td style="text-align: right;">135</td>
<td style="text-align: right;">109</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$120.00</td>
<td>$42.6K</td>
<td style="text-align: right;">186</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.8</td>
<td>$9.6</td>
<td>$9.8</td>
<td>$175.00</td>
<td>$34.3K</td>
<td style="text-align: right;">517</td>
<td style="text-align: right;">37</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Where Is DexCom Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,057,557, with DXCM's price down by -0.5%, positioned at $139.62.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About DexCom</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $162.0.
<ul>
<li>Maintaining their stance, an analyst from UBS continues to hold a Buy rating for DexCom, targeting a price of $163. </li>
<li>Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on DexCom with a target price of $161. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for DexCom, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On DexCom

4 analysts have shared their evaluations of DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for DexCom, revealing an average target of $160.0, a high estimate of $165.00, and a low estimate of $151.00. This upward trend is evident, with the current average reflecting a 7.15% increase from the previous average price target of $149.33.
<img src="https://www.benzinga.com/files/images/story/2024/1712772070_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of DexCom by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$163.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$161.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$151.00</td>
<td>$147.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of DexCom's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Discovering DexCom: A Closer Look</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Unraveling the Financial Story of DexCom</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: DexCom's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 26.9%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: DexCom's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.78%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): DexCom's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): DexCom's ROA excels beyond industry benchmarks, reaching 3.99%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.25, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: DexCom In The Eyes Of 4 Experts

UBS analyst Danielle Antalffy maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $153 to $163.

UBS Maintains Buy on DexCom, Raises Price Target to $163

Rumors

Watching DexCom; Hearing Investor Business Daily's Swingtrader Names Stock As Buy

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $148 to $161.

Citigroup Maintains Buy on DexCom, Raises Price Target to $161

The Nasdaq 100 closed lower by around 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company&rsquo;s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Micron Technology </h3>
<ul>
<li>The Trade: Micron Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mu#NASDAQ">MU</a>) EVP, Chief People Officer April S Arnzen <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 4,890 shares </a> at an average price of $119.30. The insider received around $583,377 from selling those shares.</li>
<li>What&rsquo;s Happening: Micron reported better-than-expected second-quarter financial results and issued strong third-quarter guidance on March 20, 2024.</li>
<li>What Micron Technology Does: Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips.</li>
</ul>
Have a look at our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h3>DexCom</h3>
<ul>
<li>The Trade: DexCom, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxcm#NASDAQ">DXCM</a>) EVP Chief Legal Officer Michael Jon Brown <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 2,624 shares </a> at an average price of $140.04. The insider received around $367,472 from selling those shares.</li>
<li>What&rsquo;s Happening: On March 13, RBC Capital initiated coverage on the stock with an Outperform rating and $165 price target.</li>
<li>What DexCom Does: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients.</li>
</ul>
<h3>Williams-Sonoma </h3>
<ul>
<li>The Trade: Williams-Sonoma, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wsm#NYSE">WSM</a>) CEO POTTERY BARN BRANDS Marta Benson <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 2,184 shares </a> at an average price of $313.98. The insider received around $685,721 from selling those shares.</li>
<li>What&rsquo;s Happening: On March 26, Evercore ISI Group analyst Oliver Wintermantel maintained Williams-Sonoma with an In-Line and raised the price target from $300 to $320.</li>
<li>What Williams-Sonoma Does: With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas.</li>
</ul>
<h3>Dropbox </h3>
<ul>
<li>The Trade: Dropbox, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dbx#NASDAQ">DBX</a>) CFO Timothy Regan <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 3,000 shares </a> at an average price of $24.36. The insider received around $73,074 from selling those shares.</li>
<li>What&rsquo;s Happening: On March 22, Citigroup analyst Steven Enders maintained Dropbox with a Neutral and lowered the price target from $31 to $27.</li>
<li>What Dropbox Does: Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37975916/jim-cramer-likes-crown-castle-but-cant-recommend-archer-aviation-it-has-no-earnings-powe"> Jim Cramer Likes Crown Castle, But Can&#39;t Recommend Archer Aviation: It Has &#39;No Earnings Power&#39; </a>

Insider Trades

Micron, Dropbox And 2 Other Stocks Insiders Are Selling

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 25.38% on an annualized basis producing an average annual return of 38.72%. Currently, DexCom has a market capitalization of $51.42 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 15 years ago, it would be worth $139,310.17 today based on a price of $133.38 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711391419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report), Rhythm P...

Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)

Dexcom (DXCM) Gets a Buy from Piper Sandler

In a report released today, Mathew Blackman from Stifel Nicolaus maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of...

Dexcom (DXCM) Gets a Buy from Stifel Nicolaus

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Gilead Sciences ...

Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)

The healthcare scene is home to some pretty defensive companies that aren't exactly shying away from medical innovation. With the following Strong-...

ABT, DHR, DXCM: Which "Strong Buy" Healthcare Stock Has More Upside?

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dexcom (DXCM – Research Report), OptimizeRx (OPRX ...

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)

DexCom, Insulet, Tandem seen benefitting the most in diabetes survey - Wells Fargo

Top 50 stocks with the highest sensitivity to interest rates changes - GS

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AptarGroup (ATR – Research Report), Dexcom (DXCM – R...

Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunome (IMNM – Research Report), Dyne Therapeutics...

Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)

AAPL

ABBV

ALDX

ANET

CSCO

FOXA

GILD

HBAN

IMNM

MPWR

NCLH

OPRX

ORCL

PANW

PAYC

PODD

REGN

RYTM

SCHW

SMCI

TNDM

TSCO

TSLA

TTWO

XLRE

Press Releases

Synchron Appoints Andy Rasdal to Board of Directors

Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Dexcom Announces Upcoming Conference Presentation

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

-

-

-

-

-

-

-

-

-

-

-

-

-

-

DexCom Stock (NASDAQ:DXCM), Short Interest Report

People Also Watch